Intrathecal Administration of Neutralizing Antibody against Fas Ligand Suppresses the Progression of Experimental Autoimmune Encephalomyelitis
- 18 August 2000
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 275 (1) , 164-168
- https://doi.org/10.1006/bbrc.2000.3279
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- The Effect of Apoptosis Inhibitors on Experimental Autoimmune Encephalomyelitis: Apoptosis as a Regulatory FactorBiochemical and Biophysical Research Communications, 2000
- Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitisJournal of Clinical Investigation, 2000
- Tumor Necrosis Factor α and Lymphotoxin α Are Not Required for Induction of Acute Experimental Autoimmune EncephalomyelitisThe Journal of Experimental Medicine, 1997
- Apoptosis by Death FactorCell, 1997
- Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain.The Journal of Experimental Medicine, 1996
- Antigen-specific down-regulation of myelin basic protein-reactive T cells during spontaneous recovery from experimental autoimmune encephalomyelitis: further evidence of apoptotic deletion of autoreactive T cells in the central nervous systemInternational Immunology, 1995
- Macrophage Apoptosis in the Central Nervous System in Experimental Autoimmune EncephalomyelitisJournal of Autoimmunity, 1994
- The Dale E. McFarlin memorial lecture: The immunology of the multiple sclerosis lesionAnnals of Neurology, 1994
- Lethal effect of the anti-Fas antibody in miceNature, 1993
- Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitroAnnals of Neurology, 1988